DSM 265
Alternative Names: DSM-265; PfSPZLatest Information Update: 19 Dec 2022
Price :
$50 *
At a glance
- Originator Monash University; University of Texas Southwestern Medical Center; University of Washington
- Developer Center for Infectious Disease Research; Fred Hutchinson Cancer Research Center; Medicines for Malaria Venture; Takeda; United States Department of Defense
- Class Antimalarials; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 15 Dec 2022 National Institute of Allergy and Infectious Diseases plans a phase I trial for Malaria (Prevention) in Mali (IV) (NCT05652504)
- 28 Sep 2021 Discontinued - Phase-I/II for Malaria (In adults, In volunteers, Combination therapy) in Australia (PO)
- 28 Sep 2021 Discontinued - Phase-II for Malaria (In adults) in Peru (PO)